Mizuho Securities analyst Mara Goldstein weighed in on Iovanace Biotherapeutics (NASDAQ: IOVA) after the company announced that Maria Fardis, Ph.D ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments FDA

Iovance Biotherapeutics (IOVA) Plunges 33% as CEO Resigns Day after BLA DelayMay 19, 2021 12:03 PM Iovance Biotherapeutics (IOVA) Halted on LUDPMay 19, 2021 12:01 PM Iovance Biotherapeutics (IOVA) CEO ResignsMay 19, 2021 12:01 PM Form 8-K IOVANCE BIOTHERAPEUTICS, For: May 18May 19, 2021 11:48 AM Iovanace Biotherapeutics (IOVA) PT Lowered to $35 at Piper SandlerMay 19, 2021 11:01 AM Pre-Open Stock Movers 05/19: (LPTH) (RETA) (TTWO) Higher; (MARA) (RIOT) (COIN) Lower (more...)May 19, 2021 9:29 AM Iovanace Biotherapeutics (IOVA) PT Lowered to $33 at Stifel on BLA PushMay 19, 2021 8:05 AM Iovanace Biotherapeutics (IOVA) PT Lowered to $51 at Chardan Capital Markets on BLA DelayMay 19, 2021 7:58 AM Iovanace Biotherapeutics (IOVA) PT Lowered to $48 at Truist SecuritiesMay 19, 2021 7:04 AM Iovanace Biotherapeutics (IOVA) PT Lowered to $40 at BarclaysMay 19, 2021 5:34 AM Iovanace Biotherapeutics (IOVA) PT Lowered to $51 at OppenheimerMay 19, 2021 5:07 AM Iovanace Biotherapeutics (IOVA) PT Lowered to $93 at Goldman SachsMay 19, 2021 3:40 AM Iovanace Biotherapeutics (IOVA) PT Lowered to $43 at JMP SecuritiesMay 19, 2021 1:54 AM After-Hours Stock Movers 05/18: (LPTH) (PRPL) (TTWO) Higher; (IOVA) (QUIK) (LAD) Lower (more...)May 18, 2021 5:52 PM Iovance Biotherapeutics (IOVA) Provides Regulatory Update for Lifileucel Potency Assays, BLA Submission Now Expected H1 2022May 18, 2021 4:31 PM Iovance Biotherapeutics Provides Regulatory Update for Lifileucel Potency AssaysMay 18, 2021 4:30 PM